| Literature DB >> 29768970 |
I F Ricarte1, L A Dutra1,2, F F Abrantes1, F F Toso1, O G P Barsottini1, G S Silva1,2, A W S de Souza3, D Andrade3.
Abstract
Neurological involvement in antiphospholipid antibody syndrome (APS) is common, and its occurrence increases morbidity and mortality. Patients may present variable neurological involvement, such as cerebrovascular disease, cognitive dysfunction, headache, seizures, movement disorders, multiple sclerosis-like syndrome, transverse myelitis and ocular symptoms. Most neurological manifestations are associated with thrombosis of the microcirculation or of large vessels; nonetheless, there is compelling evidence suggesting that, in some cases, symptoms are secondary to an immune-mediated pathogenesis, with direct binding of aPL on neurons and glia. Herein we describe clinical characteristics and management of neurological APS manifestations.Entities:
Keywords: APS; Antiphospholipid syndrome; antiphospholipid antibodies; central nervous system; neurological manifestations; stroke
Mesh:
Substances:
Year: 2018 PMID: 29768970 DOI: 10.1177/0961203318776110
Source DB: PubMed Journal: Lupus ISSN: 0961-2033 Impact factor: 2.911